Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

Benzinga · 2d ago
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.